MCID: NRM008
MIFTS: 30

Neuromyelitis Optica Spectrum Disorder

Categories: Rare diseases, Neuronal diseases, Eye diseases

Aliases & Classifications for Neuromyelitis Optica Spectrum Disorder

MalaCards integrated aliases for Neuromyelitis Optica Spectrum Disorder:

Name: Neuromyelitis Optica Spectrum Disorder 49
Neuromyelitis Optica 69
Nmosd 49

Classifications:



Summaries for Neuromyelitis Optica Spectrum Disorder

MalaCards based summary : Neuromyelitis Optica Spectrum Disorder, also known as neuromyelitis optica, is related to neuromyelitis optica and multiple sclerosis. An important gene associated with Neuromyelitis Optica Spectrum Disorder is AQP4 (Aquaporin 4). The drugs Mitoxantrone and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include brain, b cells and spinal cord.

Related Diseases for Neuromyelitis Optica Spectrum Disorder

Diseases in the Neuromyelitis Optica family:

Neuromyelitis Optica Spectrum Disorder

Diseases related to Neuromyelitis Optica Spectrum Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Related Disease Score Top Affiliating Genes
1 neuromyelitis optica 11.2
2 multiple sclerosis 10.6
3 myelitis 10.5
4 optic neuritis 10.4
5 neuritis 10.4
6 transverse myelitis 10.3
7 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.3
8 cervicitis 10.2
9 retinitis 10.2
10 episodic pain syndrome, familial, 1 10.2
11 myasthenia gravis 10.2
12 myasthenia gravis congenital 10.2
13 sjogren syndrome 10.2
14 cerebritis 10.2
15 internuclear ophthalmoplegia 10.1
16 encephalitis 10.1
17 lymphoma 10.1
18 mycobacterium tuberculosis 1 9.9
19 parotitis 9.9
20 myopathy 9.9
21 meningoencephalitis 9.9
22 encephalopathy 9.9
23 acute cervicitis 9.9
24 connective tissue disease 9.9
25 hypersomnia 9.9
26 autoimmune disease 9.9
27 autoimmune lymphoproliferative syndrome, type v 9.9
28 cortical blindness 9.9
29 mature b-cell neoplasm 9.9
30 occipital neuralgia 9.9
31 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.9
32 thyroiditis 9.9
33 methotrexate-associated lymphoproliferative disorders 9.9
34 systemic lupus erythematosus 9.9
35 b-cell lymphomas 9.9
36 arachnoiditis 9.9
37 myocarditis 9.9
38 scleroderma, familial progressive 9.9
39 follicular lymphoma 9.9
40 influenza 9.9
41 spinal arachnoiditis 9.9
42 hemolytic anemia 9.9
43 epilepsy 9.9
44 lung disease 9.9
45 anemia, autoimmune hemolytic 9.9
46 hepatitis 9.9
47 spondylosis 9.9
48 lupus erythematosus 9.9
49 galactorrhea 9.9
50 hepatitis b 9.9

Graphical network of the top 20 diseases related to Neuromyelitis Optica Spectrum Disorder:



Diseases related to Neuromyelitis Optica Spectrum Disorder

Symptoms & Phenotypes for Neuromyelitis Optica Spectrum Disorder

Drugs & Therapeutics for Neuromyelitis Optica Spectrum Disorder

Drugs for Neuromyelitis Optica Spectrum Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 81)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
2
Mycophenolic acid Approved Phase 4 24280-93-1 446541
3
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5 Analgesics Phase 4
6 glucocorticoids Phase 4,Phase 3,Phase 1
7 Topoisomerase Inhibitors Phase 4
8 Hormone Antagonists Phase 4,Phase 3,Phase 1
9 Hormones Phase 4,Phase 3,Phase 1
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1
11 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1
12 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1
13 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1
14 Anti-Bacterial Agents Phase 4
15 Anti-Infective Agents Phase 4
16 Antibiotics, Antitubercular Phase 4
17 Antitubercular Agents Phase 4
18
Prednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 50-24-8 5755
19
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 83-43-2 6741
20
Azathioprine Approved Phase 2, Phase 3 446-86-6 2265
21
rituximab Approved Phase 2, Phase 3,Phase 1 174722-31-7 10201696
22 Prednisolone acetate Phase 3,Phase 1,Phase 2
23 Methylprednisolone acetate Phase 3,Phase 1,Phase 2
24 Methylprednisolone Hemisuccinate Phase 3,Phase 1,Phase 2
25 Gastrointestinal Agents Phase 3,Phase 1
26 Neuroprotective Agents Phase 3,Phase 1
27 Antiemetics Phase 3,Phase 1
28 Prednisolone hemisuccinate Phase 3,Phase 1,Phase 2
29 Prednisolone phosphate Phase 3,Phase 1,Phase 2
30 Protective Agents Phase 3,Phase 1
31 Autonomic Agents Phase 3,Phase 1
32 Rho(D) Immune Globulin Phase 3,Phase 2
33 gamma-Globulins Phase 3,Phase 2
34 Immunoglobulins Phase 3,Phase 2,Phase 1
35 Immunoglobulins, Intravenous Phase 3,Phase 2
36 Immunosuppressive Agents Phase 2, Phase 3, Phase 1
37 Antimetabolites Phase 2, Phase 3
38 Antimetabolites, Antineoplastic Phase 2, Phase 3
39 Antibodies Phase 3,Phase 2,Phase 1
40 Antirheumatic Agents Phase 2, Phase 3, Phase 1
41 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
42
Metoclopramide Approved, Investigational Phase 2 364-62-5 4168
43
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 657311 5754
44
Histamine Approved, Investigational Phase 1, Phase 2 51-45-6, 75614-87-8 774
45
4-Aminopyridine Approved Phase 2 504-24-5 1727
46
Cetirizine Approved Phase 1, Phase 2 83881-51-0 2678
47
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
48
Mesna Approved, Investigational Phase 1, Phase 2 3375-50-6 598
49
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
50
Dexamethasone Approved, Investigational, Vet_approved Phase 1, Phase 2 50-02-2 5743

Interventional clinical trials:

(show all 46)

# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
2 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
3 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Enrolling by invitation NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
4 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
5 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
6 A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders Recruiting NCT03330418 Phase 3
7 Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Recruiting NCT03350633 Phase 2, Phase 3 Tocilizumab Injection;Azathioprine
8 A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02200770 Phase 2, Phase 3
9 Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD Recruiting NCT02028884 Phase 3 satralizumab (SA237);Placebo
10 A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) Active, not recruiting NCT01892345 Phase 3 Eculizumab
11 Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD Active, not recruiting NCT02073279 Phase 3 satralizumab (SA237);Placebo
12 An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Enrolling by invitation NCT02003144 Phase 3
13 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3 Intravenous Methylprednisolone;Intravenous Immunoglobulin
14 Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Unknown status NCT02249676 Phase 2
15 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
16 Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. Completed NCT01845584 Phase 2 NPB-01
17 Neuromyelitis Optica (NMO) & Cetirizine Completed NCT02865018 Phase 1, Phase 2 cetirizine
18 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Completed NCT00904826 Phase 1, Phase 2 Eculizumab
19 Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Completed NCT02166346 Phase 2 Dalfampridine;Placebo
20 Hematopoietic Stem Cell Transplant in Devic's Disease Recruiting NCT00787722 Phase 1, Phase 2
21 Scrambler Trial for Pain in NMOSD Recruiting NCT03452176 Phase 2
22 Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder Active, not recruiting NCT02893111 Phase 2 Bortezomib
23 A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD Active, not recruiting NCT03062579 Phase 1, Phase 2 Tocilizumab
24 Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica Terminated NCT01339455 Phase 1, Phase 2
25 Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses Unknown status NCT02087813 Phase 1 Alpha1-antitrypsin;methylprednisolone
26 C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation Completed NCT01759602 Phase 1 C1-esterase inhibitor (Cinryze)
27 Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations Completed NCT01777412 Phase 1 Bevacizumab
28 Safety and Tolerability of Rituximab in Neuromyelitis Optica Completed NCT00501748 Phase 1 Rituximab
29 Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B Recruiting NCT02283671 Phase 1
30 Central Pain Study for ABX-1431 Recruiting NCT03138421 Phase 1 ABX-1431 HCl;Placebo
31 Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Active, not recruiting NCT02276963 Phase 1 Ublituximab
32 Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct Unknown status NCT01024985
33 Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis Completed NCT03122873
34 Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02836327
35 The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS) Recruiting NCT02850705
36 The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders Recruiting NCT01623076
37 The French Multiple Sclerosis Registry Recruiting NCT02889965
38 The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset Recruiting NCT02886377
39 Optical Coherence Tomography and Optic Neuritis (OCTON) Recruiting NCT02573792
40 Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients Recruiting NCT02789670
41 Stem Cell Ophthalmology Treatment Study II Recruiting NCT03011541
42 Maintenance Plasma Exchange for Neuromyelitis Optica Active, not recruiting NCT01500681
43 Biobank For MS And Other Demyelinating Diseases Active, not recruiting NCT00445367
44 Pathologic-MRI Findings in Atypical IIDD Active, not recruiting NCT03121105
45 Stem Cell Ophthalmology Treatment Study Enrolling by invitation NCT01920867
46 Optic Neuritis Differential Diagnosis Study Not yet recruiting NCT03370965

Search NIH Clinical Center for Neuromyelitis Optica Spectrum Disorder

Genetic Tests for Neuromyelitis Optica Spectrum Disorder

Anatomical Context for Neuromyelitis Optica Spectrum Disorder

MalaCards organs/tissues related to Neuromyelitis Optica Spectrum Disorder:

38
Brain, B Cells, Spinal Cord, Eye, Hypothalamus, Lung, Whole Blood

Publications for Neuromyelitis Optica Spectrum Disorder

Articles related to Neuromyelitis Optica Spectrum Disorder:

(show top 50) (show all 257)
# Title Authors Year
1
Development of Neuromyelitis Optica Spectrum Disorder and Spinal Arachnoid Cysts in a Patient With Intractable Epilepsy. ( 29379967 )
2018
2
Worldwide prevalence of neuromyelitis optica spectrum disorders. ( 29436488 )
2018
3
Bortezomib for Neuromyelitis Optica Spectrum Disorder: A New Therapeutic Option for the More Severe Forms? ( 29159372 )
2018
4
Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report. ( 29361915 )
2018
5
Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients. ( 29367170 )
2018
6
Association of Visual Impairment in Neuromyelitis Optica Spectrum Disorder With Visual Network Reorganization. ( 29297041 )
2018
7
Bortezomib for Neuromyelitis Optica Spectrum Disorder: A New Therapeutic Option for the More Severe Forms? ( 29159373 )
2018
8
Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder. ( 29406915 )
2018
9
Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region. ( 29359475 )
2018
10
MRI Features of Aquaporin-4 Antibody-Positive Longitudinally Extensive Transverse Myelitis: Insights into the Diagnosis of Neuromyelitis Optica Spectrum Disorders. ( 29449281 )
2018
11
Eye movement abnormalities in AQP4-IgG positive neuromyelitis optica spectrum disorder. ( 29249386 )
2018
12
Spectrum of MRI brain lesion patterns in neuromyelitis optica spectrum disorder: a pictorial review. ( 29388807 )
2018
13
Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders. ( 29414283 )
2018
14
Bortezomib for Neuromyelitis Optica Spectrum Disorder: A New Therapeutic Option for the More Severe Forms?-Reply. ( 29159366 )
2018
15
Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis. ( 29414288 )
2018
16
Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder. ( 29414297 )
2018
17
The IL-10-producing regulatory B cells (B10 cells) and regulatory T cell subsets in neuromyelitis optica spectrum disorder. ( 29349658 )
2018
18
A Rare Presentation of Neuromyelitis Optica Spectrum Disorders. ( 29434480 )
2018
19
Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. ( 29406904 )
2018
20
Retinal segmented layers with strong aquaporin-4 expression suffered more injuries in neuromyelitis optica spectrum disorders compared with optic neuritis with aquaporin-4 antibody seronegativity detected by optical coherence tomography. ( 28057643 )
2017
21
Deep gray matter atrophy in neuromyelitis optica spectrum disorder and multiple sclerosis. ( 28009104 )
2017
22
Orbital Ectopic Lymphoid Follicles with Germinal Centers in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorders. ( 29387055 )
2017
23
Anti-N-methyl-D-aspartate receptor(NMDAR) antibody encephalitis presents in atypical types and coexists with neuromyelitis optica spectrum disorder or neurosyphilis. ( 28056870 )
2017
24
Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders. ( 28080220 )
2017
25
Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. ( 28451627 )
2017
26
Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. ( 28920766 )
2017
27
Pregnancy in neuromyelitis optica spectrum disorder: A multicenter study from South China. ( 28017203 )
2017
28
Reply to letter to the editor: Dimethyl fumarate for patients with neuromyelitis optica spectrum disorder by Pitarokoili and Gold. ( 28747150 )
2017
29
Neuromyelitis optica spectrum disorder diagnostic criteria: Sensitivity and specificity are both important. ( 28080211 )
2017
30
Can Wernekink commissure syndrome and wall-eyed bilateral internuclear ophthalmoplegia be ascribed to neuromyelitis optica spectrum disorder? ( 28681309 )
2017
31
Acute-Onset Severe Occipital Neuralgia Associated With High Cervical Lesion in Patients With Neuromyelitis Optica Spectrum Disorder. ( 28699327 )
2017
32
Cervical cord myelin water imaging shows degenerative changes over one year in multiple sclerosis but not neuromyelitis optica spectrum disorder. ( 28725551 )
2017
33
Aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder with recurrent short partial transverse myelitis and favorable prognosis: Two new cases. ( 28580873 )
2017
34
Pruritus may be a common symptom related to neuromyelitis optica spectrum disorders. ( 28427688 )
2017
35
Treatment for paraneoplastic neuromyelitis optica spectrum disorder (NMOsd): Probable effects of tocilizumab for both cancer and NMOsd. ( 29353735 )
2017
36
Neuromyelitis Optica Spectrum Disorders. ( 28391784 )
2017
37
Convergence spasm due to aquaporin-positive neuromyelitis optica spectrum disorder. ( 29260017 )
2017
38
MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease? ( 29194504 )
2017
39
Comparison of cognitive and brain grey matter volume profiles between multiple sclerosis and neuromyelitis optica spectrum disorder. ( 28846745 )
2017
40
Aquaporin-4 positive neuromyelitis optica spectrum disorders secondary to thrombopenic purpura: A case report. ( 28079804 )
2017
41
Methotrexate-associated lymphoproliferative disorder in a patient with neuromyelitis optica spectrum disorder: An implication for pathogenesis mediated by Epstein-Barr virus. ( 28716244 )
2017
42
Paraneoplastic Neuromyelitis Optica Spectrum Disorder: A single center cohort description with two cases of histological validation. ( 29291482 )
2017
43
Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder. ( 28400553 )
2017
44
Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea. ( 28058965 )
2017
45
Neuromyelitis optica spectrum disorder related tonic spasms responsive to lacosamide. ( 28427706 )
2017
46
Clinical commentary on 'Aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder with recurrent short partial transverse myelitis and favorable prognosis: Two new cases', by Wang et al. ( 28580877 )
2017
47
LC-MS/MS Analysis of Erythrocyte Thiopurine Nucleotides and Their Association With Genetic Variants in Patients With Neuromyelitis Optica Spectrum Disorders Taking Azathioprine. ( 27941536 )
2017
48
A case of neuromyelitis optica spectrum disorder (NMOSD) with SjAPgren's syndrome manifested only brain involvement by preceding parotitis. ( 28132975 )
2017
49
Comparison of brain and spinal cord magnetic resonance imaging features in neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody. ( 28427704 )
2017
50
Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. ( 28831548 )
2017

Variations for Neuromyelitis Optica Spectrum Disorder

Expression for Neuromyelitis Optica Spectrum Disorder

Search GEO for disease gene expression data for Neuromyelitis Optica Spectrum Disorder.

Pathways for Neuromyelitis Optica Spectrum Disorder

GO Terms for Neuromyelitis Optica Spectrum Disorder

Sources for Neuromyelitis Optica Spectrum Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....